Physician profile
Peter J Ocarroll
NPI 1811190812
$137,378.96
in general payments reported to CMS, 2019-2025
65 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,140 · 2020: $25K · 2021: $24K · 2022: $35K · 2023: $9,163 · 2024: $7,977 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $8,689 · Travel and Lodging: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,281.25 |
| Food and Beverage | $8,689.25 |
| Travel and Lodging | $318.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $78,586.51 | 2019-2025 | |
| Amgen INC. | $27,822.80 | 2019-2025 | Uplizna |
| Allergan, INC. | $17,319.63 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,492.40 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $1,356.77 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Biogen, INC. | $1,102.00 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Lilly USA, LLC | $863.36 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Supernus Pharmaceuticals, INC. | $846.98 | 2019-2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $749.61 | 2019-2025 | |
| Pfizer INC. | $620.62 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $577.41 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Sk Life Science, INC. | $494.87 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $485.29 | 2019-2022 | |
| Eisai INC. | $444.06 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $319.08 | 2019-2025 | Ingrezza, Ongentys |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ocarroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.